NEW DELHI : Gilead Science Inc is planning to grant long-term licenses to Indian drug-makers for generic versions of its promising covid-19 drug remdesivir, even as health activists are pushing the government to revoke the three patents given to the US-based firm citing procedural issues.
Late Tuesday, the US based firm said it is in discussions with “some of the world’s leading chemical and pharmaceutical manufacturing companies" to produce remdesivir for Europe, Asia and the developing world through at least 2022, while also negotiating long-term voluntary licenses with several generic drugmakers in India and Pakistan for developing countries. “Gilead will provide appropriate technology transfers to facilitate this production.